CXL-1427

Cimlanod or CXL-1427 is an experimental drug for the treatment of acute decompensated heart failure. It was created by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitric oxide donor.[1]

CXL-1427 is a prodrug of CXL-1020.[2]

A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]

References

  1. ↑ Alternative Names: BMS-986231; CXL 1427; HNO Donor. "BMS 986231 - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
  2. ↑ Alternative Names: CXL-1020. "CXL 1020 - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
  3. ↑ http://www.mdedge.com/ecardiologynews/article/109035/heart-failure/nitroxl-prodrug-shows-promise-acute-heart-failure
  4. ↑ "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.